Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: Information has been received from Sanofi Pasteur MSD (SPM) (manufacturer control # DK-1577272925-2016005137) as part of business agreement on 11-MAY-2016. Case received from a physician on 09-MAY-2016 with reference number DK-DKMA-WBS-0003370/ADR 23460513. A 13-year-old female adolescent patient received GARDASIL (batch number lot not rep, Dose 1) via intramuscular route on 21-Oct-2008, GARDASIL (batch number lot not rep, Dose 2) via intramuscular route on 23-Dec-2008, GARDASIL (batch number lot not rep, Dose 3) via intramuscular route on 21-Apr-2009. The patient experienced Arthralgia in 2009, Myalgia in 2011, Back pain in 2009, Muscle tics in 2010, Muscle weakness in 2011, Sensory disturbances in the skin when touched in 2012, Dizziness, orthostatic in 2010, Shortness of breath at light load in 2012, Sweating in 2012, Increased susceptibility to infections in 2011, Hair loss in 2010, Lower abdominal pain in 2009, Tiredness in 2010, Headache in 2014, Light sensitivity in 2014, Nausea in 2008, Frequent urination in 2011, Mood swings in 2011, Muscle cramps in 2010, Changed temperature regulation in 2012, Complication with school and Commercial College student completed in 4 years instead of 3 years on an unknown date and Abdominal pain on an unknown date. History around side effect: Impedes School and Commercial College student out of 4 years instead of 3 years. Other Vaccines: No. Other Medicines: No. The patient was admitted to hospital on an unspecified date. The patient''s outcome was reported as Not Recovered/Not Resolved.
Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166